Detalhe da pesquisa
1.
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Am J Gastroenterol;
2019 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694863
2.
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one are Associated with Bile Acid Diarrhea in Patients with Crohn's Disease.
Clin Gastroenterol Hepatol;
2018 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30448597
3.
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Am J Gastroenterol;
2018 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30390030
4.
Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases.
Dig Dis Sci;
2018 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361807
5.
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
Inflamm Bowel Dis;
2018 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30295781
6.
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol;
2018 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30268561
7.
Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death.
Proc Natl Acad Sci U S A;
115(39): E9192-E9200, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209212
8.
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
Inflamm Bowel Dis;
2018 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30165490
9.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Am J Gastroenterol;
113(9): 1345-1354, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29946178
10.
Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease.
Inflamm Bowel Dis;
24(11): 2366-2376, 2018 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29889233
11.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Gastroenterology;
155(3): 687-695.e10, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29857091
12.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
Inflamm Bowel Dis;
24(11): 2461-2467, 2018 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29788240
13.
Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance.
J Immunol;
200(12): 4012-4023, 2018 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703862
14.
Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures.
Inflamm Bowel Dis;
24(6): 1316-1320, 2018 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29697797
15.
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
J Crohns Colitis;
12(6): 635-643, 2018 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29370397
16.
Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease.
Clin Transl Gastroenterol;
9(1): e132, 2018 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29345635
17.
Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation.
Am J Gastroenterol;
112(10): 1621, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28978958
18.
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Gastroenterol Clin North Am;
46(3): 627-644, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838419
19.
Endoscopic Surveillance in Long-standing Colitis.
Curr Treat Options Gastroenterol;
15(3): 429-439, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28803403
20.
The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1.
Gut;
66(9): 1584-1596, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27325418